CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CSF1-CAR 特异性靶向 CSF1R⁺ 胰腺癌细胞与肿瘤相关巨噬细胞
英文原题：CSF1-CAR Specifically Targets CSF1R + Pancreatic Cancer Cells and Tumor-Associated Macrophages.
查看英文原题
CSF1-CAR Specifically Targets CSF1R + Pancreatic Cancer Cells and Tumor-Associated Macrophages.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
强免疫抑制性肿瘤微环境和非特异性靶点是恶性肿瘤CAR-T 细胞治疗面临的问题。GEPIA数据库显示，CSF1R在胰腺癌组织中的表达高于正常组织；M2巨噬细胞是造成免疫抑制性肿瘤微环境（TME）的主要因素，这提示CSF1R是合适抗原。CSF1是CSF1R的天然配体，因此我们构建了CSF1-CAR，并在体外检测其对肿瘤细胞和巨噬细胞的细胞毒效应。结果显示，CSF1-CAR-T 细胞可依赖CSF1R表达裂解肿瘤细胞。同时，CSF1-CAR-T 也可裂解CSF1R阳性M2巨噬细胞，提示CSF1-CAR-T 细胞既能清除肿瘤细胞，也能重塑TME。
展开英文摘要原文
A highly suppressive tumor immune microenvironment and nonspecific target endow malignant tumors with CAR-T cells. CSF1R is highly expressed on pancreatic cancer tissues compares with normal tissues in GEPIA database and M2 macrophages mainly contributing to the suppressive tumor microenvironment (TME), suggesting that CSF1R is a suitable antigen. CSF1 is the natural ligand of CSF1R, so we constructed a CSF1-CAR and tested its cytotoxic effect on tumor cells and macrophages in vitro.
Our results demonstrated that CSF1-CAR-T cells can lyse tumor cells dependent on CSF1R expression. Meanwhile, CSF1-CAR-T also lyse CSF1R + M2 macrophages, suggesting that CSF1-CAR-T cells play a role in eliminating tumor cells and remodeling the TME.
论文信息
- 作者
- Zhu Y、Sun R、Fan J、Ma H、Sun B
- 单位
- Division of Abdominal Tumor Multimodality Treatment and Laboratory of Cell Engineering and Immunotherapy, Cancer Center and State Key Laboratory of Respiratory Health and Multimorbidity and Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.China
- 期刊
- Journal of immunotherapy (Hagerstown, Md. : 1997)2025 Sep 1
- 原文标识
- PubMed 40375821 · DOI 10.1097/CJI.0000000000000563